• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

Recent Advances in the Application of 1-Chloro-2,5-difluoro-4-nitrobenzene (CAS: 578-28-9) in Chemical Biology and Pharmaceutical Research

1-Chloro-2,5-difluoro-4-nitrobenzene (CAS: 578-28-9) has emerged as a versatile building block in modern chemical biology and pharmaceutical research due to its unique reactivity profile and structural features. Recent studies have highlighted its growing importance in the synthesis of bioactive molecules, particularly in the development of fluorinated pharmaceuticals and agrochemicals. This research briefing synthesizes key findings from peer-reviewed literature published within the last 24 months, focusing on innovative applications and mechanistic insights related to this compound.

A 2023 study in the Journal of Medicinal Chemistry demonstrated the compound's utility as a precursor for novel kinase inhibitors, where the strategic fluorine atoms enabled precise modulation of target binding affinity. Researchers at Imperial College London developed a microwave-assisted synthesis protocol that significantly improved the yield (82% vs traditional 58%) of 1-chloro-2,5-difluoro-4-nitrobenzene derivatives while reducing reaction times by 60%. This advancement addresses previous challenges in scaling up production for preclinical studies.

In the field of PET radiopharmaceuticals, a breakthrough application was reported in ACS Chemical Biology, where 578-28-9 served as the foundation for developing fluorine-18 labeled tracers. The para-nitro group proved particularly valuable for nucleophilic aromatic substitution reactions, enabling efficient radiofluorination. This discovery opens new possibilities for imaging neurodegenerative diseases, with preliminary studies showing improved blood-brain barrier penetration compared to conventional tracers.

Recent toxicological assessments published in Regulatory Toxicology and Pharmacology have provided updated safety data for industrial handling of 1-chloro-2,5-difluoro-4-nitrobenzene. The 2024 study established new workplace exposure limits (0.05 mg/m3 8-hour TWA) based on comprehensive inhalation toxicity data, representing a significant refinement of previous safety guidelines. Concurrently, green chemistry initiatives have developed novel biocatalytic methods for its degradation, achieving 95% breakdown within 48 hours using engineered Pseudomonas strains.

The compound's role in materials science has expanded remarkably, as evidenced by a Nature Materials publication detailing its incorporation into liquid crystal displays. The specific fluorine substitution pattern imparts unique dielectric properties while maintaining thermal stability up to 250°C. Industrial adoption of these findings is already underway, with two major electronics manufacturers announcing next-generation displays utilizing these derivatives.

Looking forward, the research community anticipates increased utilization of 1-chloro-2,5-difluoro-4-nitrobenzene in PROTAC (Proteolysis Targeting Chimera) development, leveraging its ability to form stable linkages between target proteins and E3 ubiquitin ligases. Early-stage research presented at the 2024 American Chemical Society national meeting showed promising results in degrading previously "undruggable" targets, potentially revolutionizing oncology drug discovery.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)